Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 10
Submit an article Journal homepage
553
Views
1
CrossRef citations to date
0
Altmetric
Letters to the Editor

Durable remissions in two adult patients with Burkitt lymphoma following anti-CD19 CAR T-cell therapy: a single center experience

Samantha J. Seittera Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USAView further author information
,
Paul H. McClellanda Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USAORCID Iconhttps://orcid.org/0000-0002-3119-6531View further author information
ORCID Icon,
Mark A. Ahlmanb Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, MD, USAView further author information
,
Stephanie L. Goffa Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USAView further author information
,
James C. Yanga Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USAView further author information
,
Lori McIntyrea Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USAView further author information
,
Steven A. Rosenberga Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USAView further author information
,
James N. Kochenderfera Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USAView further author information
&
Jennifer N. Brudnoa Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USACorrespondence[email protected]
View further author information
 show all
Pages 2469-2473 | Received 24 Mar 2022, Accepted 06 May 2022, Published online: 09 Jun 2022

References

  • Teras LR, DeSantis CE, Cerhan JR, et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016;66(6):443–459.
  • Crombie J, LaCasce A. The treatment of Burkitt lymphoma in adults. Blood. 2021;137(6):743–750.
  • Short NJ, Kantarjian HM, Ko H, et al. Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma. Am J Hematol. 2017;92(6):E114–E117.
  • Dunleavy K. Approach to the diagnosis and treatment of adult Burkitt’s lymphoma. J Oncol Pract. 2018;14(11):665–671.
  • Avigdor A, Shouval R, Jacoby E, et al. CAR T cells induce a complete response in refractory Burkitt lymphoma. Bone Marrow Transplant. 2018;53(12):1583–1585.
  • Du J, Zhang Y. Sequential anti-CD19, 22, and 20 autologous chimeric antigen receptor T-cell (CAR-T) treatments of a child with relapsed refractory Burkitt lymphoma: a case report and literature review. J Cancer Res Clin Oncol. 2020;146(6):1575–1582.
  • Zhang W, Yang J, Zhou C, et al. Early response observed in pediatric patients with relapsed/refractory Burkitt lymphoma treated with chimeric antigen receptor T cells. Blood. 2020;135(26):2425–2427.
  • Zhou X, Ge T, Li T, et al. CAR19/22 T cell therapy in adult refractory Burkitt’s lymphoma. Cancer Immunol Immunother. 2021;70(8):2379–2384.
  • Wang T, Feng M, Luo C, et al. Successful treatment of pediatric refractory Burkitt lymphoma PTLD after liver transplantation using anti-CD19 chimeric antigen receptor T-Cell therapy. Cell Transplant. 2021;30:963689721996649.
  • Liu Y, Deng B, Hu B, et al. Sequential different B cell antigen-targeted CAR T-cell therapy for pediatric refractory/relapsed Burkitt lymphoma. Blood Adv. 2021;138(Suppl 1):257–257.
  • Kochenderfer JN, Dudley ME, Kassim SH, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33(6):540–549.
  • Kochenderfer JN, Somerville RPT, Lu T, et al. Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels. J Clin Oncol. 2017;35(16):1803–1813.
  • Brudno JN, Lam N, Vanasse D, et al. Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma. Nat Med. 2020;26(2):270–280.
  • Sweetenham JW, Pearce R, Taghipour G, et al. Adult Burkitt's and Burkitt-like non-Hodgkin's lymphoma-outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: results from the European Group for Blood and Marrow Transplantation. J Clin Oncol. 1996;14(9):2465–2472.
  • Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019;20(1):31–42.
  • Schuster SJ, JULIET Investigators. Tisagenlecleucel in diffuse large B-Cell lymphoma. Reply. N Engl J Med. 2019;380(16):1586.
  • Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (Transcend NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839–852.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.